Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 3, 2007 Matthew Crews	Henry Schein Herds Immunity The vaccine distributor hopes a strong 2007 will help revive its earnings. Value investors should put Henry Schein on their watch lists until it presents a greater margin of safety.
The Motley Fool June 22, 2004 Dave Marino-Nachison	Schein Over Europe On Friday, dental and medical products distributor Henry Schein completed the purchase of a set of European operations with roughly $340 million in sales for the fiscal year ended Sept. 30
BusinessWeek April 4, 2005 Gene G. Marcial	Schein Gets Over The Flu Henry Schein, the top producer of flu vaccines in the U.S., reported notable fourth-quarter earnings despite the mandated stoppage of vaccine production last year.
The Motley Fool July 28, 2005 Rich Duprey	Chiron's Tragic Quarter The biotech vaccine maker barely breaks even but boasts of its ability to meet full-year expectations.
The Motley Fool March 3, 2005 Rich Duprey	Chiron Back From the Dead British authorities give vaccine manufacturer the go-ahead to restart facility. Investors can breathe a sigh of relief.
The Motley Fool October 18, 2005 Rich Duprey	Chiron's Sickly Forecast The flu vaccine maker further reduces its estimated dose production. With its earnings release due next week, perhaps Chiron was simply preparing investors for a jolt.
The Motley Fool January 26, 2005 Rich Duprey	Chiron's Earnings Ills Flu vaccine manufacturer expected to report significantly lower profits.
The Motley Fool October 6, 2004 Rich Duprey	Chiron Sneezes, Investors Catch Cold British authorities shut down the pharmaceutical's only U.S. flu vaccine manufacturing facility. This may in fact be an opportunity to scoop up a beleaguered stock at fire sale prices.
The Motley Fool September 7, 2005 Rich Duprey	Is Chiron Worth It? The vaccine maker rejects Novartis' bid of $40 a share as inadequate. How much should the pharma pay? Investors, take note.
The Motley Fool June 17, 2005 W.D. Crotty	Biotech's Apple Dumpling Gang Chiron has made a number of financial and planning mistakes in the production of its flu vaccine.
The Motley Fool December 10, 2004 Rich Duprey	Regulators Quarantine Chiron The FDA sends a warning letter on the heels of a suspension extension by British authorities. Whether shares of the pharmaceutical ultimately finish up or down, the one-two punch from U.S. and British authorities still points to an ailing company.
The Motley Fool December 7, 2004 Brian Gorman	ID Biomedical's Shot in the Arm The company appears well-positioned for the coming years, but it may be best to stay cautious on the company.
The Motley Fool October 31, 2005 Rich Duprey	Chiron Not Immune to Merger The board accepts a sweetened buyout offer from Swiss pharmaceutical firm Novartis. Investors, take note.
The Motley Fool May 25, 2006 Stephen D. Simpson	Same Old Patterson Even deep drilling can't unearth a discount at this dental and veterinary supply distributor. What's more aggravating is having to pay this multiple for the business.
The Motley Fool October 28, 2005 Rich Duprey	Chiron's Bird Flu Contract As Asian bird flu becomes the crisis du jour, this flu vaccine biotech is awarded a hefty contract.
The Motley Fool October 14, 2005 Rich Duprey	Chiron Ready to Fly Flu vaccine maker readies first shipments as flu season begins and avian flu fears rise.
The Motley Fool January 6, 2005 Dave Marino-Nachison	Oxford Blues The apparel maker is pulling back its fiscal 2005 EPS estimates. Oxford still looks like a company that's growing in the right places and making smart strategic moves. Investors seem to agree.
The Motley Fool September 1, 2005 Stephen D. Simpson	Novartis Keeps Gorging Offering to buy the remainder of Chiron for $4.5 billion may up this company's execution risk over the next few quarters. Investors, take note.
The Motley Fool February 3, 2005 Dave Marino-Nachison	The Flap at American Eagle American Eagle is making the casual apparel business look easy. Q1 earnings per share are seen at between $0.43 and $0.45, up from $0.36 in 2004.
The Motley Fool November 8, 2006 Rich Duprey	BioLase Brightens Smiles: Fool by Numbers The dental laser maker released fiscal third-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool January 14, 2005 Rich Duprey	Chiron's Mythical Flu Vaccine The vaccine maker does not know when or if it will be able to start manufacturing again. Investors should pay close attention.
The Motley Fool December 3, 2004 Dave Marino-Nachison	Christopher & Banks Disappoints The women's apparel retailer surprised investors with surprisingly bad Q4 guidance.
The Motley Fool July 5, 2006 Rich Duprey	Flu Vaccine Deja Vu The country's largest vaccine maker, Sanofi Aventis, gets an FDA warning letter reminiscent of the 2004 debacle.
The Motley Fool June 14, 2005 Rich Duprey	Chiron's Credit Conundrum Standard & Poor's downgrades the biotech's credit rating on seemingly old news. Why now?
BusinessWeek January 31, 2005 Arlene Weintraub	Chiron's Flu Aches May Last Awhile Its vaccine rivals are gaining traction -- and its other businesses are just so-so
The Motley Fool December 21, 2004 Rich Duprey	Chiron Requests a Second Thought Had the vaccine maker simply issued a press release with the incorrect information, it might be understandable, but investors might feel more at ease if it had gotten it right when it filed documents with the SEC.
The Motley Fool May 26, 2005 Brian Gorman	Flu Vaccines' Unhealthy Competition The vaccine business is notoriously tricky. Given the nature of the business, respectable returns are predicated on high volumes. New competitors in the flu-fighting niche could make all companies worse off.
The Motley Fool March 9, 2005 Rich Duprey	Chiron Bundles Bad News The flu vaccine maker's bad news bonanza can't mask that it's overvalued.
The Motley Fool March 16, 2006 Rich Duprey	Chiron's Shareholder Revolt Hedge funds oppose the biotech's buyout by pharmaceutical giant Novartis. Investors, take note.
The Motley Fool September 21, 2005 Rich Duprey	A Shot of Reality for Chiron Novartis warns pharma it's willing to walk away from takeover bid. Does Chiron have the wherewithal to go it alone? Investors, take note.
The Motley Fool November 23, 2005 Stephen D. Simpson	Is It Safe for Patterson? A tougher market and high valuation don't make this dental, veterinary, and rehab supplier an especially compelling investment idea.
The Motley Fool May 27, 2005 Rich Duprey	Glaxo's Flu Vaccine Booster The drug giant's return could give the U.S. flu vaccine market a shot in the arm.
The Motley Fool October 22, 2004 Rich Duprey	Chiron Reports Profit, But So What? The flu vaccine debacle overshadows the company's profits and earnings.
The Motley Fool February 23, 2010 Brian Orelli	The End of a Swine Flu Era A Food and Drug Administration advisory panel recommended yesterday that next year's seasonal flu vaccine contain the vaccine for the H1N1 virus, aka the swine flu.
BusinessWeek October 25, 2004 John Carey	A Booster Shot For Vaccines New technology could speed the development of vaccines and keep the medicine chest stocked.
The Motley Fool October 19, 2004 Rich Duprey	Chiron Crisis Creates Investor Opportunity As flu vaccine maker flames out, other companies may step in to fill the void.
The Motley Fool April 4, 2006 Rich Duprey	Chiron's Booster Shot Novartis raises its bid for the biotech a second time, appeasing dissident shareholders.
The Motley Fool February 14, 2005 Rich Duprey	Chiron Probe Goes Formal SEC upgrades investigation into vaccine manufacturer. Was Chiron was as surprised by the contamination debacle as investors and U.S. regulators were?
The Motley Fool September 2, 2005 Rich Duprey	Will Flu Vaccine Catch Cold? The CDC says we may have as many as 97 million doses this year, but that's a best-case scenario. This year again, it's Chiron causing the uncertainty.
The Motley Fool March 2, 2004 Seth Jayson	The Shine at Schein The medical supplier continues its solid growth.
The Motley Fool October 5, 2004 Alyce Lomax	No Cheer for Chiron A U.K. regulatory body suspended its manufacturing license because of contamination. The company's misstep adds up to another rough flu season.
The Motley Fool February 9, 2007	McAfee's Firewall: Fool by Numbers The Internet security company released fourth-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights...
The Motley Fool December 13, 2005 Stephen D. Simpson	A Toothache at Sybron Dental Investors bail out in the wake of the company's fourth-quarter announcement.
The Motley Fool May 24, 2007	The ABCs of CA: Fool by Numbers The IT management software maker released fourth-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool August 25, 2005 Stephen D. Simpson	Another Cavity for Patterson Two straight disappointing quarters have drilled the medical distributor's stock.
The Motley Fool January 24, 2007	Bank of America Deposits Growth: Fool by Numbers The financial giant released fourth-quarter 2006 earnings: Income Statement Highlights... Ratio Checkup... Balance Sheet Highlights...
The Motley Fool February 9, 2007	A Shot of Income for MedImmune: Fool by Numbers The pharmaceutical released earning for the fourth-quarter 2006: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool April 17, 2007 Rich Duprey	BioLase Darkens Smiles The dental laser maker warns that quarterly revenues will be dramatically lower. Investors, take note.
The Motley Fool October 29, 2004 Selena Maranjian	Flu Shots for the Elite The flu shot shortage offers some food for thought for investors. Here are some statistics showing the establishment has some problems with the priorities when it comes to the flu.
The Motley Fool February 14, 2006 Tim Beyers	Akamai's Need for Speed: Fool by Numbers Akamai Technologies released fourth-quarter 2005 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...